Samsung Electronics Targets Global Precision Medicine Market with Next-Gen Semiconductors

Samsung Electronics is making a strategic move into the global precision medicine market as competition in the artificial intelligence (AI) sector intensifies and growth in the global smartphone market slows. The company aims to secure key technologies necessary for entering the precision medicine field, strengthening its future growth foundation.

On June 10, Samsung Electronics announced that it has invested $175 million (approximately 268.8 billion won) in Element Biosciences, a U.S.-based genetic analysis company, securing a majority shareholder position.

Samsung previously participated in Element's Series D funding round in July 2024. With this investment, Element plans to accelerate the commercialization of next-generation gene sequencing and multiomics ecosystems. The company aims to expand its product roadmap in large-scale global clinical and diagnostic fields.

Samsung is particularly focused on Element's next-generation gene sequencing technology and multiomics. Multiomics is a technology that analyzes various biological information, such as RNA and proteins, to show how DNA actually functions. This approach can help identify the root causes of diseases more accurately and aid in the development of new drugs, making it a key technology for next-generation precision medicine.

Since launching its mid-sized DNA sequencing device, AVITI, in 2022, Element has rapidly expanded its presence in the global market. The Element sequencing devices are primarily used in biotechnology laboratories, research institutions, and hospital research. Multiomics products are expected to be utilized by pharmaceutical companies in the future.

In the future, DNA sequencing data is expected to be combined with clinical data from hospitals, as well as everyday data such as sleep and exercise, ultimately enabling personalized medical services. Samsung plans to strengthen its strategic partnership with Element through this expanded investment to create synergies.

Meanwhile, industry experts predict that the global precision medicine market will reach approximately $143.6 billion by 2030. Key drivers for this market include the increasing demand for personalized treatments and a growing preference for companion diagnostics and genetic testing.

A medical industry insider stated, "The future of the global precision medicine market presents opportunities in the tumor, rare disease, infectious disease, and blood disorder sectors, and it is regarded as a promising market."